• DOI:10.1016/S0140-6736(05)67528-9
Corpus ID: 11825315

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

@article{Dormandy2005SecondaryPO,
  title={Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial},
  author={J. Dormandy and B. Charbonnel and D. Eckland and E. Erdmann and O. B. O. E. investigators},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={1279-1289}
}

• J. Dormandy, B. Charbonnel, +2 authors O. B. O. E. investigators
• Published 2005
• Medicine, Computer Science
• The Lancet

BACKGROUND Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. METHODS We did a prospective, randomised controlled trial in 5238 patients with type 2… Expand

View on Elsevier

orbi.uliege.be

Save to Library

Create Alert

Cite

Launch Research Feed